While TAM-targeted therapies have shown promising results in other cancer types, this approach remains under investigated in bladder cancer (112).Molecular characterization of bladder cancer has identified several recurrent genetic alterations, including mutations in TERT promoter regions, FGFR3, TP53, PIK3CA, and STAG2 genes, along with various chromatin-modifying genes (113). The gene discussed is FGFR3; the disease is urinary bladder cancer.